Navigation Links
New Review on PROSTVAC(TM) Published by Key Investigators From NCI
Date:7/1/2009

KVISTGAARD, Denmark, July 1 /PRNewswire-FirstCall/ -- A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most comprehensive and updated Review on PROSTVAC(TM) so far.

Quote from the article: "Preliminary clinical trials have indicated negligible toxicity, and Phase II trials have suggested a survival benefit after treatment with PROSTVAC(TM), especially in patients with indolent disease characteristics."

Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are very pleased that the scientific experts once again confirm their positive view on PROSTVAC(TM) and the potential use of the vaccine in earlier stages of the disease. We are looking forward to publish more data at a later stage."

Background information:

PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical development that has the potential to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks prostate cancer cells. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects. In contrast, PROSTVAC(TM) has the potential to extend survival with improved quality of life. PROSTVAC is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement with Bavarian Nordic's U.S.-based subsidiary, BN ImmunoTherapeutics.

In clinical trials to date PROSTVAC(TM) and related PSA containing poxviral vaccines have been investigated in more than 500 patients for 10 years.

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN(R) is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
2. China Animal Welfare Law Under Review While 36,000 Dogs Culled
3. Advanced Life Sciences Announces Outcome of FDAs Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
4. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
5. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
6. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
7. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
8. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
9. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
10. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
11. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016 Global Cervical Dysplasia Market: ... global cervical dysplasia market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/7/2016)... Dec 7, 2016 Research and Markets has ... End User - Global Forecast to 2021" report to their offering. ... , , ... Billion by 2021, growing at a CAGR of 7.3% during the forecast ... growing prevalence of cancer and rapidly increasing geriatric population across the globe ...
(Date:12/7/2016)... , Dec. 7, 2016  Palatin Technologies, ... has closed on a previously disclosed underwritten public ... Canaccord Genuity acted as sole book-running manager, Roth ... Capital Markets acted as co-manager for the offering. ... $15.4 million in net proceeds, allowing us to ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an ... Remote Control through a new partnership with Splashtop Inc. This remote control for ... solutions to help businesses maximize their uptime and productivity. , Wavelink offers powerful ...
(Date:12/7/2016)... GA (PRWEB) , ... December 07, 2016 , ... In ... route to respond to an emergency medical call when he lost control of his ... After being extricated from his vehicle, he was transported to Atlanta Medical Center, where ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... A quote ... an outpouring of comments on social media that offer a rare glimpse into the ... leading ADHD authority and New York Times bestselling author, has described people with ADHD ...
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... consultation services to residents in the Sacramento/Folsom region, is initiating a charity event ... , The Another Choice Another Chance treatment center in Sacramento works to provide ...
Breaking Medicine News(10 mins):